Patents
US 11890265 B2: Cancer starvation therapy
- Granted
- 2024-02-06
- Filed
- 2019-03-25 application 16363758
- Type
- Utility · 1 claim
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
Source: PVGPATDIS, file of 2026-04-10 (ipg240206.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| SERBIG PHARMACEUTICALS CORPORATION 4 patents | US company or organization | Bayamón, PR | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Pedro Anastacio Serrano-Ojeda | San Juan, PR | 4 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/198 | PVGPATDIS, file of 2026-04-10 |
| A61N | Electrotherapy; magnetotherapy; radiation therapy; ultrasound therapy | A61N5/02 | PVGPATDIS, file of 2026-04-10 |
| C07F | Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium | C07F1/00 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2020-11-18 | Assignment Assignment of assignor's interest | SERRANO-OJEDA, PEDRO ANASTACIO signed 2020-10-30 | SERBIG PHARMACEUTICALS CORP. BAYAMON, PR | 54410/483 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.